Observational analysis reports risk of autoimmune diseases in patients with primary immune thrombocytopenia, indicating relevance of antinuclear antibody positivity.
Objective Primary immune thrombocytopenia (ITP) is a heterogeneous disease. antinuclear antibody (ANA)-positive primary ITP may resemble the preclinical stage of autoimmune diseases (AIDs), but is still considered primary ITP due to a controversial AIDs risk assessment in this group. This study aimed to clarify the risk of AIDs in ANA-positive patients with primary ITP.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: